Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 37 of 5804
-
Promising malaria vaccine candidates enter key trial in african children
⭐️ VACCINE ⭐️ OngoingThis is a Phase IIb randomised controlled trial of the safety, immunogenicity and efficacy of the malaria vaccine candidates R78C with Matrix-M™, and the combination of RH5.1 and R21 with Matrix-M™, in children aged 5-36 months in Burkina Faso.
Phase: PHASE2 • Sponsor: University of Oxford • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 11:01 UTC
-
Gene therapy Follow-Up: 15-Year watch for sickle cell patients
Disease control Recruiting nowThis is a Long-term Follow-up (LTFU) study in patients who received BEAM-101 in the parent study (Study BTX-AUT-001). Eligible patients who received BEAM-101 will be asked to participate in this LTFU study prior to completing Study BTX-AUT-001. Patients who enter into this study …
Sponsor: Beam Therapeutics Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
Experimental gene therapy aims to help boys with rare muscle disease breathe easier
Disease control Recruiting nowX-linked myotubular myopathy (XLMTM) is a rare and serious condition present at birth where the muscles do not work properly. There are currently no approved therapies for XLMTM. The protein myotubularin is needed for muscle development, movement and breathing. A gene called MTM…
Phase: PHASE1, PHASE2 • Sponsor: Astellas Gene Therapies • Aim: Disease control
Last updated Jul 17, 2026 00:00 UTC
-
New pill aims to keep pancreatic cancer away after surgery
Disease control Recruiting nowThe purpose of this study is to evaluate the safety and efficacy of a novel RAS(ON) inhibitor compared to standard of care (SOC) observation only.
Phase: PHASE3 • Sponsor: Revolution Medicines, Inc. • Aim: Disease control
Last updated Jul 09, 2026 00:00 UTC
-
New hope for lung cancer: experimental drug ZG006 takes on chemo
Disease control Recruiting nowThe main objective is to compare ZG006 with Investigator-Selected Chemotherapy on prolonging overall survival (OS).
Phase: PHASE3 • Sponsor: Suzhou Zelgen Biopharmaceuticals Co.,Ltd • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
New hope for bladder cancer: targeted drug combo trial launches
Disease control Recruiting nowThe purpose of this study is to test a new medicine, vepugratinib, in comparison with placebo, to see if it is safe and can help people with a bladder cancer that is advanced or has spread. Vepugratinib or placebo will be administered in combination with enfortumab vedotin and p…
Phase: PHASE3 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jul 15, 2026 00:00 UTC
-
Engineered immune cells take on tough lymphoma in new trial
Disease control Recruiting nowDALY II Japan is a phase II, multi-center, single arm study to evaluate the efficacy, safety, and pharmacokinetics of zamtocabtagene autoleucel (MB-CART2019.1) in patients with relapsed and/or refractory diffuse large B cell lymphoma (DLBCL) after receiving at least two lines of …
Phase: PHASE2 • Sponsor: Miltenyi Biomedicine GmbH • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
New hope for colorectal cancer: experimental drug faces off against avastin
Disease control Recruiting nowThe purpose of this study is to learn more about a new medicine called PF-08634404, and how well it works in people with cancer of the colon or rectum (CRC)). The goal is to understand if the new study medicine, combined with chemotherapy that is approved for colorectal cancer, c…
Phase: PHASE3 • Sponsor: Pfizer • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
Magic Mushroom-Derived drug enters final trial for depression
Symptom relief Recruiting nowThe purpose of this study is to determine the efficacy, safety and tolerability of CYB003 compared to matching placebo as adjunctive treatment in patients with MDD. For more information about the EMBRACE study, including participating study locations, and to register your intere…
Phase: PHASE3 • Sponsor: Cybin IRL Limited • Aim: Symptom relief
Last updated Jul 02, 2026 00:00 UTC
-
Pfizer launches massive trial of c. diff vaccine for seniors
⭐️ VACCINE ⭐️ Recruiting nowThe purpose of the study is to learn about how effective, safe, and tolerable the Clostridioides difficile (C. difficile) vaccine is in decreasing the number of C. difficile infections (pCDI) in adults 65 years of age or older. The participants will receive either the C. diffici…
Phase: PHASE3 • Sponsor: Pfizer • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 12:37 UTC
-
New COVID-19 vaccine trial targets variants in Middle-Aged adults
⭐️ VACCINE ⭐️ OngoingThis study is designed to find out how well the COVID-19 vaccine protects people 50 to 64, who don't have any serious health problems, compared to a group that receives a vaccine that doesn't contain an ingredient to protect against COVID-19 (placebo).
Phase: PHASE3 • Sponsor: BioNTech SE • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 12:06 UTC
-
Brain cancer breakthrough? GammaTile trial aims to boost survival
Disease control Recruiting nowThis is a Phase 3 prospective, randomized, superiority, open-label, multi-site study. The overview of this study is as follows: * A Screening/Baseline Period of 21 days. During this time, patients will be randomized into a 1:2 allocation of Arm A:Arm B. * A Perioperative/Operati…
Phase: PHASE3 • Sponsor: GT Medical Technologies, Inc. • Aim: Disease control
Last updated Jul 11, 2026 00:00 UTC
-
New hope for rare lung cancer: targeted pill tepotinib faces final test
Disease control Recruiting nowThe hypothesize is that tepotinib is more effective than the investigator's choice of treatment in patients with MET-mutated NSCLC who have progressed after at least one first-line treatment. The main benefit concerns patient access to tepotinib. There is currently no access to …
Phase: PHASE3 • Sponsor: Intergroupe Francophone de Cancerologie Thoracique • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC
-
New drug duo aims to outsmart stomach cancer
Disease control Recruiting nowCIME is a multicenter, randomised, comparative, open-label phase III study aiming to compare the survival of patients suffering from MSI-H/dMMR locally advanced or metastatic oeasogastric adenocarcinoma treated by a bi-immunotherapy (experimental arm) versus standard current trea…
Phase: PHASE3 • Sponsor: Centre Leon Berard • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New drug combo aims to revive immune response in lung cancer
Disease control Recruiting nowTHIO is a first-in-class small molecule telomere targeting agent, in development for the treatment of non-small cell lung cancer (NSCLC) in combination with cemiplimab (LIBTAYO®). THIO is preferentially incorporated into telomeres sequence in telomerase-positive cells leading to …
Phase: PHASE3 • Sponsor: Maia Biotechnology • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
New shot could help kids with tough leukemia
Disease control OngoingThe main objective of this study is to evaluate the safety and efficacy of SC blinatumomab in children below 12 years of age.
Phase: PHASE1, PHASE2 • Sponsor: Amgen • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
New pill takes on tough pancreatic cancer in major trial
Disease control Recruiting nowThis study plans to enroll participants with previously treated metastatic pancreatic cancer and harbor centrally confirmed KRAS G12D mutation. These participants are required to experience disease progression on or after at least one prior standard systemic therapy containing fl…
Phase: PHASE3 • Sponsor: Genfleet Therapeutics (Shanghai) Inc. • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
New asthma drug could cut attacks with just two shots a year
Disease control Recruiting nowThe objective of this study is to assess the potential for GB-0895 treatment to improve the health of adolescents and adults with severe asthma that is uncontrolled by inhaled corticosteroids (ICS) and conventional asthma controllers. The study details include: Study treatment:…
Phase: PHASE3 • Sponsor: Generate Biomedicines • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC
-
Last hope drug trial for kids with fatal brain disease
Disease control OngoingCree Leukoencephalopathy (CLE) is a very rare and severe brain disease that mainly affects members of the Cree communities in Northern Quebec. It causes the white matter of the brain-the part that helps nerves communicate-to slowly break down. As the disease progresses, children …
Phase: NA • Sponsor: McGill University Health Centre/Research Institute of the McGill University Health Centre • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
Supercharged immune cells take on advanced melanoma
Disease control Recruiting nowThis is a phase I/II clinical trial of a single dose of CD40L-augmented TIL administered in patients with advanced melanoma (Cohort 1: Cutaneous acral melanoma, cutaneous non-acral melanoma, (n=26); Cohort 2: Mucosal melanoma, uveal melanoma, (n=10)). Patients will undergo an exc…
Phase: PHASE1, PHASE2 • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC